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Abstract: Wear debris associated periprosthetic osteolysis represents a major pathological 
process associated with the aseptic loosening of joint prostheses. Naringin is a major flavonoid 
identified in grapefruit. Studies have shown that naringin possesses many pharmacological 
properties including effects on bone metabolism. The current study evaluated the influence 
of naringin on wear debris induced osteoclastic bone resorption both in vitro and in vivo. The 
osteoclast precursor cell line RAW 264.7 was cultured and stimulated with polymethylmethacry-
late (PMMA) particles followed by treatment with naringin at several doses. Tartrate resistant 
acid phosphatase (TRAP), calcium release, and gene expression profiles of TRAP, cathepsin 
K, and receptor activator of nuclear factor-kappa B were sequentially evaluated. PMMA chal-
lenged murine air pouch and the load bearing tibia titanium pin-implantation mouse models 
were used to evaluate the effects of naringin in controlling PMMA induced bone resorption. 
Histological analyses and biomechanical pullout tests were performed following the animal 
experimentation. The in vitro data clearly demonstrated the inhibitory effects of naringin in 
PMMA induced osteoclastogenesis. The naringin dose of 10 µg/mL exhibited the most significant 
influence on the suppression of TRAP activities. Naringin treatment also markedly decreased 
calcium release in the stimulated cell culture medium. The short-term air pouch mouse study 
revealed that local injection of naringin ameliorated the PMMA induced inflammatory tissue 
response and subsequent bone resorption. The long-term tibia pin-implantation mouse model 
study suggested that daily oral gavage of naringin at 300 mg/kg dosage for 30 days signifi-
cantly alleviated the periprosthetic bone resorption. A significant increase of periprosthetic 
bone volume and regaining of the pin stability were found in naringin treated mice. Overall, 
this study suggests that naringin may serve as a potential therapeutic agent to treat wear debris 
associated osteolysis.
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Introduction
Osteolysis represents a major pathological process that occurs during aseptic prosthetic 
loosening and osteoporosis, and is characterized by regional bone loss, inflammation, 
and bone demineralization. Total joint replacement is a successful surgical procedure 
to restore joint function and to repair joints damaged by traumatic injury or arthritis. 
Although failure of total joint replacement due to infection and surgical error has 
been greatly reduced in recent years, aseptic prosthetic loosening remains the most 
common complication and represents a major problem for the long-term success and 
survival of prostheses.1 It appears that wear debris generated at the bone–implant 
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interface plays a critical role in initiating local inflammation 
and periprosthetic bone loss, leading to the ultimate failure 
of the prostheses.2
Studies have suggested that the receptor activator of 
nuclear factor-kappa B ligand (RANKL)/osteoprotegerin 
pathway plays a key role in bone metabolism and  osteolysis.3 
RANKL, expressed by macrophages, osteoblasts, marrow 
stromal cells, and lymphocytes, binds to its physiologi-
cal receptor, receptor activator of nuclear factor-kappa B 
(RANK), on the cell surface of osteoclasts and osteoclast 
precursors, resulting in proliferation, differentiation, and 
maturation of osteoclasts and subsequent local osteolysis.4 
Mice genetically deficient for RANKL or RANK often 
exhibit severe osteopetrosis,5 indicating that RANKL and 
RANK are essential for osteoclast development. Osteoclasts 
are characterized by high expression of tartrate resistant acid 
phosphatase (TRAP) and cathepsin K (CPK), gene products 
that contribute to the mineral dissolution and resorption of 
the organic matrix of bone.6,7
Naringin is a compound extracted from citrus fruits such 
as grapefruit and is reported to be beneficial in the treat-
ment and prevention of osteoporosis.8 In vitro studies have 
revealed that naringin actively promoted the differentiation 
of mesenchymal stem cells to osteogenic cells.9 An in vivo 
study10 reported that naringin suppressed osteoclast forma-
tion, while another study using osteoclast precursor cells 
showed that naringin abrogated osteoclastogenesis and bone 
resorption via inhibition of RANK induced nuclear factor-
kappa B (NF-κB) and extracellular signal-regulated kinase 
(ERK) activation.11 However, there is lack of knowledge on 
naringin’s therapeutic influence on particulate wear debris 
associated osteolysis.
We hypothesized that naringin may inhibit osteoclasto-
genesis and exert therapeutic effects on wear debris associ-
ated osteolysis. Using both in vitro and in vivo experimental 
approaches, this study has tested naringin’s possible therapeu-
tic effects and its efficacy in polymethylmethacrylate (PMMA) 
induced inflammation, osteoclastogenesis, and osteolysis.
Materials and methods
Particle preparation
PMMA particles with a mean diameter of 0.33 µm 
(0.33±0.019 µm) were obtained from a commercial source 
(Polysciences, Warrington, PA, USA). The size and distribution 
of the particles were evaluated with a Coulter particle counter 
(Beckman Coulter, Inc., Indianapolis, IN, USA) and by scan-
ning electron microscopy (SEM; Hitachi S-2400, Japan).12 
The particles were washed in 70% ethanol solution and heat 
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Figure 1 raW 264.7 cell culture stimulation and trap assay.
Notes: (A) raW 264.7 cells cultured (200×) and (B) raW 264.7 cells stimulated 
with polymethylmethacrylate (PMMa) particles (200×). (C) PMMa particle 
stimulation significantly increases RAW 264.7 cell TRAP function while naringin 
inhibited it in a concentration dependent manner. a concentration of 10 µg/ml 
worked best for the inhibition. *Denotes P,0.05 when compared to PMMa.
Abbreviations: PMMa, polymethylmethacrylate; TraP, tartrate resistant acid 
phosphatase.
 sterilized. A limulus assay (Endosafe; Charles Rivers Labora-
tories, Charlestown, SC, USA) was then performed on particles 
to ensure they were free of endotoxin. Particles were suspended 
in sterile phosphate-buffered saline (PBS) and stored at 4°C.
raW 264.7 cell cultures stimulation  
and TraP assay
The mouse RAW 264.7 macrophage cell line (American 
Type Culture Collection, Manassas, VA, USA) was used for 
in vitro assessment of the naringin effects. RAW 264.7 cells 
were seeded on 8-chamber slides in Dulbecco’s Modified 
Eagle’s Medium (DMEM) containing 10% fetal bovine 
serum and antibiotics (100 units/mL penicillin + 100 µg/
mL streptomycin) at 37°C in a humidified incubator with 5% 
CO
2
. PMMA particles in 5 mg/mL were added to a 96-well 
plate with 1×105 RAW 264.7 cells/well. For treatment groups, 
naringin was added along with PMMA suspension concen-
trations ranging from 0.1 µg/mL to 100 µg/mL. RANKL 
(10 ng/mL) was added to wells of the positive control group. 
Cell culture media were collected after 3 days culture for 
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TRAP activity determination as described elsewhere.13 In 
brief, 20 µL of supernatant from RAW 264.7 cell culture 
medium was added to a 96-well plate and 80 µL of freshly 
prepared reaction buffer (0.33 mol/L acetic acid, 0.167% 
Triton X-100, 0.33 mol/L sodium chloride, 3.33 mol/L 
ethylenediaminetetraacetic acid at pH 5.5, 1.5 mg/mL of 
ascorbic acid, 7.66 mg/mL of sodium tartrate, 3 mg/mL of 
4-nitrophenylphosphate) was added. The reaction was left for 
1 hour at 37°C in the dark, and then stopped with 100 µL of 
0.3 mol/L sodium hydroxide. The colorimetric changes were 
measured at 405 nm with 650 nm as the reference using a 
microplate spectrophotometer (Molecular Devices LLC, 
Sunnyvale, CA, USA). Meanwhile, the cells were fixed in 
buffered acetone and processed for histochemical TRAP 
staining using a commercial kit (387A-1 KT; Sigma-Aldrich, 
St Louis, MO, USA) as detailed previously.14
real time quantitative polymerase  
chain reaction (Pcr)
RAW 264.7 cells were cultured in the presence of 1% PMMA 
particles for 6 hours before collection for RNA extraction. 
For naringin interference experiments (dimethyl sulfoxide 
[DMSO] was used as vehicle to dissolve the compound), 
RAW 264.7 cells were pretreated with naringin for 3 hours 
before addition of PMMA particles. Real time quantitative 
PCR was carried out according to the manufacturer’s instruc-
tions (StepOnePlus Real-Time PCR System; Life Technolo-
gies, Carlsbad, CA, USA). Primers used in this study were as 
follows: TRAP (Cat# QT00131012; QIAGEN Inc., Valencia, 
CA, USA); RANK, 5′-GGGTGGGGGGCAGACTTCAC-3′ 
(forward), 5′- ATGCCAGCAGCCTGCACCAG-3′ (reverse); 
CPK, 5′-CGTGCAGCAGAACGGAGGCA-3′ (forward), 
5′-TAGCTGCCTTTGCCGTGGCG-3′ (reverse).
To standardize the target gene level with respect to 
variability in RNA and cDNA, the housekeeping gene 
18S was used as an internal control. Normalization and 
analysis of the reporter signals (∆Rn) at the threshold cycle 
were recorded using the machine firmware.
establishment of the bone resorption air 
pouch model and naringin intervention
All experimental procedures and protocols were approved by 
our Institutional Animal Care and Use Committee (IACUC). 
The air pouch model of bone resorption was established 
in our laboratories as described previously.15 Briefly, air 
pouches were generated by injection of sterile air on the 
back of female BALB/c mice (8 to 10 weeks of age). At day 
6 after air pouch formation, a proximal or distal section of 
the femur, or a section of calvarium from the congeneric lit-
termate donors, was surgically implanted into the established 
air pouches. Mice were randomly divided into four groups 
(six mice each) the next day. Three experimental groups 
of mice were given PMMA particle (0.3 mL of 10 mg/mL 
stock) injection into each pouch to provoke inflammatory 
responses, and respectively received intrapouch injection of 
1) 150 mg/kg of naringin in 0.2 mL DMSO; 2) 30 mg/kg 
naringin in 0.2 mL DMSO; and 3) 0.2 mL DMSO vehicle. 
The mice in the control group without PMMA stimulation 
received 0.2 mL of PBS. Mice were kept for 7 more days 
before being sacrificed in a CO
2
 chamber, and the whole 
pouches were surgically harvested. Pouch fluid plus 0.2 mL of 
rinsing saline was collected as pouch lavage for free calcium 
determination. The remainder of the pouch tissue with the 
intact bone–implant was either snap frozen for frozen tissue 
sectioning (calvarium embedded pouches for TRAP stain), 
or fixed in 10% buffered formalin (Thermo Fisher Scientific, 
Waltham, MA, USA) for paraffin embedding.
establishment of the titanium-pin  
(Ti-pin) model on bone resorption  
and naringin intervention
To study oral administration of naringin and its long-term 
influence on particle-induced periprosthetic bone resorp-
tion, a newly characterized mouse proximal tibia Ti-pin 
failure model was adopted.16 Female BALB/c mice 10 to 
12 weeks old were used in this experiment, and all proce-
dures were approved by Wichita State University IACUC. 
A flat-headed Ti-pin (5 mm long ×0.8 mm diameter, 12 mm 
flat top; specially manufactured by Stryker Orthopaedics, 
Inc., Mahwah, NJ, USA) was surgically inserted into the 
proximal tibia to a depth where the head of the pin was flush 
with the knee joint surface. At 3 weeks after surgery (when 
the implanted pin gained osteointegration), the mice were 
divided into three groups (six mice per group): two groups 
received daily intragastric gavages with high dose (1500 mg/
kg body weight) or low dose (300 mg/kg) of naringin, while 
the third group of mice received PBS gavages as controls. At 
4 weeks postsurgery, all animals were given an intra-articular 
injection of PMMA particles to the implanted knee joint to 
mimic prosthetic wear. MicroCT (SCANCO viva 4.0; Scanco 
Medical, Basserdorf, Switzerland) scanning was performed 
immediately after surgery, and at 3 weeks and 7 weeks after 
the surgery to monitor the morphological bone changes. The 
Scanco MicroCT Evaluation Program V6.5-1 software was 
used for data collection. The mice were sacrificed 7 weeks 
after surgery (4 weeks after naringin intervention), and the 
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implant bearing limb collected for implant stability examina-
tion (pullout test) and histological assessments (peri-implant 
soft tissue formation, pit bone erosions, and bone collagen 
degradation). MicroCT images of the mouse proximal tibia 
around the pin were reconstructed and processed using a 
threshold of 300–700mg HA/ccm17 to calculate the BV/TV 
(bone volume/total volume) values of each specimen.
calcium release assay on mouse  
calvaria cultures and air pouch  
bone resorption model
Stimulated medium was prepared by incubation of RAW 
264.7 cells in the serum-free DMEM medium containing 
PMMA (0.2 mg/mL) for 3 days. The media were then har-
vested and stored at −80°C until use. Calvaria were collected 
from 12 week old C57BL/6 mice and dissected free of soft 
tissue. Stimulated medium from activated RAW 264.7 cells 
was diluted (1:1) in serum-free DMEM and incubated with a 
piece of calvarium for 5 days. To investigate whether naringin 
can inhibit stimulated medium-induced bone resorption, cal-
varia were cultured in the presence of naringin (10 µg/mL) 
for up to 5 days. Bone cultures without naringin treatment 
were included as controls. At the end of the experiments, the 
calcium released into the media was measured by the Calcium 
(Arsenazo) Reagent Set (Pointe Scientific, Inc., Canton, MI, 
USA).18 Briefly, 10 µL of medium was added to 190 µL of 
0.11 mM o-cresolphthalein complexone/17 mM 8-hydroxy-
quinoline/976 mM 2-amino-2-methyl-1-propanol/2 mM 
potassium cyanide solution. The intensity of the calcium-o-
cresolphthalein complexone complex was assayed at 570 nm 
on a microplate spectrophotometer (Molecular Devices). An 
aqueous calcium solution (10 mg/dL =2.5 mM) was used as 
standard. The calcium concentration was calculated using 
the following formula:
Calcium
(mmoles) 
Absorbance of sample
Absorbance of standar
=
d
  Concentration of
standard (2.5 mM).
 
×
 
  (1)
Pouch lavage samples from the bone resorption air pouch 
model experiment were also examined for free calcium con-
centration using the same procedure.
histochemical staining and image  
analysis of bone air pouch tissue
Formalin-fixed pouches with implanted bone were decalcified 
with formic acid/sodium citrate before being paraffin-embedded 
and mounted with a consistent orientation and cut to 
6 µm sections. The sections were stained with hematoxylin and 
eosin to examine bone erosion and changes in inflammatory 
parameters in pouch membranes. Histochemical TRAP staining 
was performed on frozen sectioned calvarium air pouch tissues 
to localize the osteoclast-like cells.15,19 Briefly, cryosections at 
8 µm thickness were prepared and fixed in buffered acetone 
for 30 seconds. Sections were incubated at 37°C for 1 hour in 
100 mM acetate buffer (pH 5.2), containing 0.5 mM of naphthol 
AS-BI phosphoric acid, 2.2 mM of Fast Garnet GBC, and 8 mM 
of sodium tartrate (Sigma-Aldrich). The dark purple stained 
cells along the bone surfaces were quantified as TRAP positive 
(TRAP+) cells. TRAP+ multinucleated cells containing more 
than three nuclei were counted as osteoclasts, whereas TRAP+ 
mononucleated cells were counted as preosteoclasts. A com-
puterized image analysis system with the software “Image-Pro 
Plus” (Media Cybernetics, Silver Spring, MD, USA) was used 
to analyze the local inflammation (pouch membrane thickness 
and inflammatory cell infiltration) and local osteoclastogenesis 
(TRAP+ cell counts) as described previously.14,15,19,20
Pin pullout testing
Immediately following sacrifice of the animals receiving 
proximal tibia Ti-pin implantation, the mouse limb bearing 
the titanium implant was removed by disarticulating the 
knee joint. All soft tissue around the prosthetic joint was 
carefully removed to expose the implanted pin head surface 
and proximal tibia. A custom aluminum fixture was designed 
to securely hold and align the pin for extraction. The test 
fixture utilized two razor blades which were tightened onto 
the head of the pin to securely grip the pin for removal. The 
pin and tibia were mounted to this fixture and the pin align-
ment was checked to ensure that its axis was parallel with 
the direction of extraction and orthogonal to the razor blade 
grips. With the tibia pin held by the fixture and the fixture 
mounted on the load frame, approximately 1 cm of the distal 
portion of the tibia was then cemented into a potting box 
using high strength dental cement. The cement was given at 
least 30 minutes of cure time before testing. A Bose 3200 
load frame was used to run the pin extraction test. The test 
was run under displacement control at a rate of 1 mm/min 
and the actuator position and applied load were recorded as 
a function of time using Bose WinTest® software.
statistical analysis
Alldata are presented as the mean ± standard deviation, and 
single factor analysis of variance with LSD post hoc multiple 
comparison (IBM Corporation, Armonk, NY, USA) was 
used to assess the statistical significance among groups. The 
student’s t-test (IBM) was adopted for statistical comparisons 
Drug Design, Development and Therapy 2014:8 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5
naringin for PMMa induced osteolysis
before and after treatment. In all statistical evaluations, 
P,0.05 was considered statistically significant.
Results
naringin inhibited the TraP function  
of particle induced raW 264.7 cells
PMMA particle stimulation significantly increased the func-
tion of RAW 264.7 cell trap function when compared to the 
medium group. Naringin decreased the TRAP function with 
a wide range of concentrations, and the concentration of 
10 µg/mL exhibited the most significant inhibition among 
all the concentrations tested (Figure 1).
naringin inhibition of PMMa induced 
raW 264.7 cell osteoclastogenesis
Addition of RANKL dramatically induced osteoclasto-
genesis of the RAW 264.7 cells in culture by significantly 
elevating TRAP activity and TRAP+ staining (Figure 2B). 
Challenge with PMMA particles also promoted the RAW 
264.7 cells to become TRAP+ and merge to multinucleated 
cells (Figure 2C). PMMA induced osteoclastogenesis was 
significantly inhibited by naringin treatment (10 µg/mL for 
3 days), with less multinucleated cell formation and fewer 
TRAP+ cells (Figure 2E). Real time PCR data suggested that 
PMMA particles markedly increased the gene expression 
of TRAP, CPK, and RANK (3 to 4 fold) as illustrated in 
Figure 3, whereas naringin treatment (10 µg/mL) signifi-
cantly down regulated the messenger (m)RNA expression 
of TRAP, CPK, and had a trend to downregulate the mRNA 
expression of RANK.
naringin diminished osteoclastic  
calcium release induced by stimulated  
medium from the PMMa activated raW 
264.7 cells and in the air pouch model
Naringin treatment inhibited calcium release from the cal-
varia bone in stimulated medium. Coculture of the mouse 
calvaria with stimulated medium from PMMA particle 
activated RAW 264.7 cells resulted in a markedly elevated 
calcium level in the medium after 5 days (166.47±35.19 µM) 
when compared to the controls cultured in serum-free DMEM 
medium (86.81±3.75 µM). In the presence of naringin 
(10 µg/mL), a significant decrease in calcium release into 
culture medium was observed (93.43±2.59 µM, P,0.05).
Naringin treatment also inhibited calcium release from 
the implanted bone air pouch model. The concentrations 
of calcium in the lavage fluid averaged 135.32±19.00 µM 
in the PMMA + PBS group, 137.42±24.20 µM in 
the PMMA + vehicle group, 95.61±18.26 µM in the 
PMMA + 30 mg/kg naringin group, and 50.12±15.94 µM in 
the PMMA + 150 mg/kg naringin group, respectively. A dose 
of 150 mg/kg naringin significantly decreased calcium release 
when compared to the PMMA + vehicle group (P,0.05).
naringin protected against bone  
resorption/degradation induced by  
PMMa particles in the air pouch model
A macroscopic view of the air pouches at sacrifice illustrated 
that introduction of naringin dramatically ameliorated the 
inflammatory appearance (Figure 4A) when compared to the 
vehicle controls of the PMMA particle-challenged pouches 
which remained significantly inflammatory and erythematous 
(Figure 4B). Histological analysis of hematoxylin and eosin 
stained bone implanted pouch sections exhibited extensive 
inflammatory cellular infiltration and membrane hyperplasia 
in the PMMA group (Figure 4D). Naringin treatment sig-
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Figure 2 naringin inhibited polymethylmethacrylate induced osteoclastogenesis of 
raW 264.7 cells.
Notes: (A) scanning electron micrograph image of polymethylmethacrylate 
(PMMa) particles used in the study (50,000×). Tartrate resistant acid phosphatase 
(TraP) stained raW 264.7 cells (B) stimulated with receptor activator of nuclear 
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nificantly reduced this inflammatory response (Figure 4C). 
Pouch membranes with naringin treatment (150 mg/kg) 
exhibited mean thickness of 96.18±7.67 µm, which was 
significantly less than those pouches retrieved from untreated 
animals (256.69±84.82 µm, P,0.01) (Figure 4E). Naringin 
treatment also diminished the cell density in the pouch 
membranes when compared to untreated PMMA particle 
controls (2219.42±914.13 per mm2 and 5067.13±85.60 per 
mm2, respectively) (Figure 4F).
Histochemical TRAP staining on the calvaria pouch 
model revealed ubiquitous dark purple stained osteoclast 
cells accumulated along the bone–membrane interface. While 
Figure 5B illustrates the TRAP+ cell aggregation and erosion 
pits in PMMA stimulated bone pouch, there were only small 
numbers of TRAP+ cells on naringin (150 mg/kg) treated 
specimens (Figure 5A). Figure 5C summarizes the naringin 
effects on TRAP+ cell accumulation assessed by computer-
ized image analysis. Naringin significantly decreased the 
amount of TRAP+ cellular infiltration in comparison with 
the PMMA control group.
naringin protected against long-term 
bone resorption induced by PMMa 
particles in the mouse proximal tibia  
pin-implantation model
The mice tolerated the proximal tibia Ti-pin implantation 
surgery well and ambulated with the implanted limbs after 
surgery. Daily intragastric gavage and the injection of PMMA 
particles into the prosthetic knee appeared to exert no influ-
ence on their daily activity.
MicroCT analysis suggested that oral administration 
(gavages) of naringin protected against the particle-
induced periprosthetic bone loss. At 7 weeks after surgery, 
microCT assessment indicated that the average BV/TV 
value at the peri-implant region was 43.82±18.28 in the 
300 mg/kg naringin treatment group, which was signifi-
cantly higher than the mean value of 14.10±0.48 in the 
PBS control group (P,0.05). Although there was a thera-
peutic trend for the 1500 mg/kg naringin dosage group 
(28.30±10.14), no statistical significance was reached in 
the current study.
The implanted pin pullout test was performed to 
examine the mechanical stability of the titanium implant 
post-PMMA particle challenge and naringin treatment. 
The average peak interfacial shear strength against pulling 
was 10.92±1.16, 15.21±3.46, and 6.71±2.90 Newton in the 
1500 mg/kg naringin, 300 mg/kg naringin, and PBS control 
group, respectively. Naringin treatment with 300 mg/kg 
gavage dosage significantly increased the implant stability 
(Figure 6D).
Histological evaluation of sections of prosthetic tibiae 
with titanium particle challenges revealed ubiquitous pres-
ence of inflammatory fibrous membranes at the bone–implant 
interface. However, the interface membranes in sections 
from naringin treatment groups were markedly thinner or 
even absent in some samples. Panels A to C of Figure 7 
illustrate the typical cross-sectioned histological appearance 
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of the proximal tibiae with peri-implant pseudomembrane 
formation. Figure 7D summarizes the measurements of the 
membrane thickness. The data clearly indicated that both 
daily lavage dosages of naringin significantly protected 
against the formation of the inflammatory periprosthetic 
membrane.
Discussion
Osteoclast differentiation, or osteoclastogenesis, is a multistep 
event, which includes the proliferation of osteoclast precursor 
cells, commitment of cells to the osteoclast lineage, expres-
sion of osteoclast-specific genes such as TRAP, and fusion 
into multinucleated cells. Many studies have indicated that 
inflammatory osteoclastogenesis is an important step in the 
development of aseptic loosening.21,22 Wear debris, including 
PMMA,23 ultra high molecular weight polyethylene,24 and 
cobalt-chromium and titanium alloys25 have been shown to 
exert a dramatic influence in promoting osteoclastogenesis 
and/or increasing the numbers of osteoclasts.
PMMA particles alone may be responsible for triggering 
focal bone resorption.26 Studies have shown that PMMA par-
ticles were more potent in causing bone resorption than high 
density polyethylene particles, at least in vitro.27  However, 
Skoglund and Aspenberg28 reported bone formation after 
applying PMMA particles onto a rat bone surface. They 
hypothesized that the particles may have been inactivated by 
opsonization. Another explanation may be that the particle 
size in that study ranged between 5 and 10 µm, which is at 
the upper limit for macrophage phagocytosis,29 whereas the 
particles we used were much smaller (mean size of 0.3 µm), 
causing a stronger cellular response.30
Naringin, an active ingredient identified in citrus fruits, 
has recently been demonstrated to have pharmacological 
effects in bone protection. Research using an ovariecto-
mized (OVX) mouse model reported that naringin exerted 
estrogen-like activities to improve general bone  properties.31 
It has also been postulated that naringin may reduce bone 
resorption by abrogation of osteoclastogenesis via the 
inhibition of RANKL-induced NF-κB and extracellular 
signal-regulated kinase activation.11 Naringin is also 
reported to promote bone formation in a titanium particle-
induced diabetic murine calvarial osteolysis model.32 We 
have recently reported that naringin effectively promoted 
osteoblast formation and reversed OVX-induced osteopo-
rosis.33 In this study we intended to evaluate the potential 
therapeutic influence of naringin on wear debris associated 
osteolysis. The data clearly demonstrated that naringin 
profoundly diminished calcium release from calvaria 
in the PMMA particle activated mouse RAW 264.7 cell 
cultures (in vitro) and in the inflammatory environment 
of the murine air pouch. The inhibitory effect of naringin 
on osteoclastic bone resorption was confirmed by TRAP 
staining of implanted calvaria bones. Further, we have 
shown that the addition of PMMA particles to cultured 
RAW 264.7 cells can stimulate osteoclastogenesis, while 
naringin treatment significantly abrogated that activity. 
It appears that the effects of naringin may be associated 
with the down-regulation of RANK, TRAP, and CPK gene 
transcription. Pretreatment of RAW 264.7 cells with nar-
ingin at 10 µg/mL significantly reduced the mRNA copy 
numbers when compared to the controls. While RANK is 
a receptor essential to control osteoclastogenesis,5 CPK is 
a cysteine protease that plays a critical role in osteoclastic 
bone resorption and bone collagen degradation. CPK defi-
cient mice have a mild osteopetrosis and a high number of 
osteoclasts with impaired function.34 These findings suggest 
that the action of naringin in preventing osteoclastic bone 
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Figure 6 implanted pin pullout testing.
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resorption as demonstrated in this experiment is mediated 
through the RANKL/osteoprotegerin pathway.
The air pouch model with bone implantation and particle 
stimulation developed in our laboratory provides a particle 
provoked synovial-like membrane that closely surrounds and 
interacts with implanted bone.15 Although very intriguing 
data have been obtained using this model on the therapeutic 
effects of naringin including inhibition of PMMA induced 
local inflammation and protection against bone calcium 
release, the major limitation of this model is the lack of 
blood supply to implanted bone which limits the model for 
a short-term study. We thus further examined the long-term 
therapeutic influence of naringin using the mouse model of 
knee pin-implantation failure. After daily oral administration 
for 30 days, naringin treatment effectively protected against 
PMMA particle induced periprosthetic soft tissue formation 
(Figure 7) and surrounding osteolysis (evidenced by microCT 
bone volume assessment).
Interfacial strength is a major determinant of implant 
stability and testing the interfacial strength by a biome-
chanical pullout test represents a useful means to evaluate 
implant fixation. The interfacial shear load values, peak, and 
its duration were influenced by bone bonding and provide 
an assessment of implant stability.35 We have successfully 
developed a pullout test for the mouse pin-implantation 
model, and previous studies have demonstrated that wear 
debris particles dramatically decrease the interfacial shear 
strength and result in the implant loosening.16,36 The data 
from this study suggested that daily oral gavages of naringin 
appeared beneficial in maintaining the implant stability, 
although only the lower dose treatment group reached the 
statistical significance level. Further investigation with 
increased sample size (animal numbers) is warranted to 
confirm this data. In addition, although there was no obvi-
ous side effects noticed during this 4 week daily treatment 
period and all animals sustained the gavage and naringin 
well, long-term safety evaluation of the naringin treatment 
will be determined.
Many studies have focused on the treatment dosages of 
naringin administered in vitro and in vivo. A concentration 
series of naringin was examined in vitro to assess its therapeu-
tic effects. Based on our previous investigation on naringin,33 
30 mg/kg and 150 mg/kg concentrations were used on air 
pouch injection and DMSO was used as vehicle to increase 
its solubility. To evaluate the long-term therapeutic influence 
of the compound for PMMA induced prosthetic implant loos-
ening, daily oral gavage was given to administer naringin at 
1500 mg/kg and 300 mg/kg, respectively. It is arguable to use 
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Figure 7 histological appearance of the pin implanted tibiae at 4 weeks after naringin or phosphate-buffered saline interventions.
Notes: (A) naringin at 1,500 mg/kg; (B) naringin at 300 mg/kg; (C) vehicle control; and (D) quantification summary of the periprosthetic soft tissue thickness among groups 
(**denotes P,0.01).
Abbreviation: PBs, phosphate-buffered saline.
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oral administration of naringin because naringin undergoes 
some metabolic process after oral administration.  According 
to one study,37 about 21% of administered naringin was recov-
ered in rat excreta in the form of naringin, total naringenin, 
and 4-hydroxyphenylpropionic acid, and about 60% was 
recovered in dog excreta. So naringin metabolites such as 
naringenin and naringenin glucuronide could be a possible 
authentic cause of the pharmaceutical effects. However, 
the current study suggested that daily gavages of naringin 
effectively protected against PMMA induced osteolysis and 
the prosthetic pin loosening.
In conclusion, this is the first report to our knowledge 
that demonstrates that naringin can effectively protect against 
particle induced osteoclastogenesis and bone degradation in 
both short- and long-term animal models of osteolysis. The 
data suggested that the influence of naringin may act through 
the down-regulation of RANK, TRAP, and CPK pathways. 
Our findings suggest that naringin may represent a potential 
agent for the prevention and treatment of aseptic loosening. 
Further studies are indeed warranted to evaluate its pharma-
cokinetics, toxicology, and the drug delivery strategies.
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